Delivery of pemetrexed by magnetic nanoparticles: design, characterization, <i>in vitro</i> and <i>in vivo</i> assessment

Ak, Güliz; Aksu, Didem; Çapkın, Eda; Sarı, Özge; Geboloğlu, Ilgın Kımız; Şanlıer, Şenay Hamarat

doi:10.1080/10826068.2019.1692220

Cited by 11 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The outcomes confirmed that Fe MTX NPs are efficient anticancer delivery systems and most likely play a part in future in vivo applications. Pemetrexed (PMX), similar to MTX, is a folate analog and its application was evaluated for active targeting in vitro and in vivo by Ak et al [ 292 ]. Moreover, the fusion of the targeting ligand to smarten IONPs could lead to a reduction in non-specificity and enhance the uptake of nano-formula, resulting in increased anticancer effects and minimized toxicity to healthy cells as compared to passively targeted alternatives.…”

Section: Magnetic Nanoparticle Targeting Methodsmentioning

confidence: 99%

Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects

et al. 2022

View full text Add to dashboard Cite

Iron oxide nanoparticle (IONPs) have become a subject of interest in various biomedical fields due to their magnetism and biocompatibility. They can be utilized as heat mediators in magnetic hyperthermia (MHT) or as contrast media in magnetic resonance imaging (MRI), and ultrasound (US). In addition, their high drug-loading capacity enabled them to be therapeutic agent transporters for malignancy treatment. Hence, smartening them allows for an intelligent controlled drug release (CDR) and targeted drug delivery (TDD). Smart magnetic nanoparticles (SMNPs) can overcome the impediments faced by classical chemo-treatment strategies, since they can be navigated and release drug via external or internal stimuli. Recently, they have been synchronized with other modalities, e.g., MRI, MHT, US, and for dual/multimodal theranostic applications in a single platform. Herein, we provide an overview of the attributes of MNPs for cancer theranostic application, fabrication procedures, surface coatings, targeting approaches, and recent advancement of SMNPs. Even though MNPs feature numerous privileges over chemotherapy agents, obstacles remain in clinical usage. This review in particular covers the clinical predicaments faced by SMNPs and future research scopes in the field of SMNPs for cancer theranostics.

show abstract

Section: Magnetic Nanoparticle Targeting Methodsmentioning

confidence: 99%

Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Fifteen adult BALB/c female nude mice (age, 4 weeks) were subcutaneously injected with 3 × 10 6 A549 cells in 150 μ l PBS at their right axilla. When the tumor volume had reached a median size about 100 mm 3 [ 14 ], the mice were randomly divided into 5 groups: (1) sham group: intraperitoneal injection with physiological saline; (2) 5 mg/ml UBE group: intraperitoneal injection with 5 mg/ml ubenimex; (3) 10 mg/ml UBE group: intraperitoneal injection with 10 mg/ml ubenimex; (4) 15 mg/ml UBE group: intraperitoneal injection with 15 mg/ml ubenimex; and (5) UBE + PEM group: intraperitoneal injection with 15 mg/ml ubenimex and 150 mg/ml pemetrexed. After 21 days of continuous treatment, the tumor tissues were removed and weighed and their length and width were measured to determine the tumor volume.…”

Section: Methodsmentioning

confidence: 99%

Ubenimex Combined with Pemetrexed Upregulates SOCS1 to Inhibit Lung Adenocarcinoma Progression via the JAK2-STAT3 Signaling Pathway

Chen

et al. 2022

Disease Markers

View full text Add to dashboard Cite

To study the effects of ubenimex (UBE) combined with pemetrexed (PEM) on lung adenocarcinoma cell behavior and its molecular mechanism, the tissue samples from lung adenocarcinoma patients who received PEM chemotherapy, those with PEM combined with UBE chemotherapy, and healthy volunteers were retrieved and analyzed. The expression levels of the suppressor of cytokine signaling 1 (SOCS1) in the human lung adenocarcinoma cancer cell lines A549 and PC-9 and tissues were detected by qRT-PCR. MTT assay was performed for cell proliferation. Cell apoptosis was detected by flow cytometry. Cell invasion ability was assessed using the Transwell assay. The expression levels of the JAK2/STAT3 signaling pathway proteins and apoptosis-related proteins were detected by Western blot. The antitumor effect of PEM combined with UBE was tested in nude mice using the tumor formation assay. Our results showed that UBE treatment, alone or combined with PEM, inhibited lung adenocarcinoma cell migration, invasion, and proliferation; promoted apoptosis; significantly increased the G0/G1-phase cell ratio; reduced the S-phase cell ratio; and inhibited the in vivo growth of tumor cells. UBE alone or in combination with PEM also inhibited the JAK2/STAT3 signaling pathway in lung adenocarcinoma cells. In addition, UBE combined with PEM therapy was associated with increased SOCS1 expression in patients’ serum and knocking down SOCS1 reversed the antitumor effects of UBE and PEM. Overall, combination therapy with UBE and PEM could inhibit the JAK2-STAT3 signaling pathway by upregulating SOCS1 expression to hinder the progression of lung adenocarcinoma cells.

show abstract

“…In FTIR spectrum of CS (Figure 1(A)), the prominent peak formation was detected at 3500-3000 cm -1 , corresponding to the amine and hydroxyl groups. The peak at 2875 cm -1 was caused by -OH stretching, and the absorption band of the carbonyl stretching of the secondary amide was observed at 1643 cm -1 , and the bending vibrations of the N-H were determined at 1597 cm -1 (Ak et al, 2020;Kaya et al, 2014). The bands around 1024 cm -1 (C-O-C stretching) presenting in the FTIR spectrum of sodium alginate (Figure 1(A)) were attributed to its saccharide structure.…”

Section: Synthesis and Characterization Of Nanoparticlesmentioning

confidence: 99%

Aljinat/Kitosan Nanopartiküllere Pemetrekset Adsorpsiyonu ve Kontrollü İlaç Salımı

EREK

AKTAŞ

Özdemir

et al. 2021

Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi

Self Cite

View full text Add to dashboard Cite

Pemetrexed (PEM) is used for treatment of non-small cell lung cancer. However, PEM has disadvantages like fast elimination, low bioavailability, poor tumor cell selectivity, and penetration. Thus, there is a need for using pemetrexed delivery system to increase the anticancer effect of drug in lung cancer cells and to minimize its side effects. The purpose of this study is development of alginate/chitosan nanoparticles (ACNP) that have biodegradable and non-toxic structure for effective delivery of PEM for lung cancer therapy. In the present study, ACNP were prepared using the ionic gelation method, and pemetrexed was loaded via the adsorption method. Drug adsorption efficiency was calculated to be 57.80% and characterization studies were performed. In vitro drug release tests were carried out at pH levels of 5.5 and 7.4 with pemetrexed-loaded alginate/chitosan nanoparticles (PACNP) and free pemetrexed, and both the results were subsequently compared. Up to 11% release yield was observed at pH 5.5, and the yield reached up to 7% in pH 7.4 in the 25 hours. This nanoparticle system could be investigated in vitro and in vivo in further studies for controlled release of pemetrexed.

show abstract

Delivery of pemetrexed by magnetic nanoparticles: design, characterization, in vitro and in vivo assessment

Cited by 11 publications

References 40 publications

Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects

Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects

Ubenimex Combined with Pemetrexed Upregulates SOCS1 to Inhibit Lung Adenocarcinoma Progression via the JAK2-STAT3 Signaling Pathway

Aljinat/Kitosan Nanopartiküllere Pemetrekset Adsorpsiyonu ve Kontrollü İlaç Salımı

Contact Info

Product

Resources

About